Deltex Medical Group (DEMG)

Sector:

Health Care

Index:

FTSE AIM All-Share

1.30p
   
  • Change Today:
    -0.100p
  • 52 Week High: 2.65
  • 52 Week Low: 0.90
  • Currency: UK Pounds
  • Shares Issued: 524.46m
  • Volume: 1,035,182
  • Market Cap: £6.82m
  • RiskGrade: 445

Deltex Medical Group launches 'TrueVue' haemodynamic monitoring system

By Josh White

Date: Tuesday 24 Oct 2017

LONDON (ShareCast) - (ShareCast News) - Oesophageal doppler monitoring company Deltex Medical Group announced the launch of a "revolutionary concept" in advanced haemodynamic monitoring on Tuesday - the 'TrueVue' system.
The AIM-traded firm said the TrueVue system comprised three "distinct best-in-class" advanced haemodynamic monitoring technologies on a single platform.

They included the TrueVue Doppler - a "high-end" ODM technology providing beat-to-beat imaging of cardiac output for monitoring sedated patients and easy calibration and recalibration of arterial pressure cardiac output.

It also included TrueVue Impedance - a non-invasive, high definition impedance cardiography for monitoring awake patients, both mobile and immobile.

The final monitoring technology was TrueVue Loops,, described as unique real-time biomarkers for early detection of hypo- and hyper-volaemia, hypo- and hyper-tension and real-time display of responses to treatment.

Deltex said the TrueVue system was being featured at its booth at Anesthesiology 2017, the annual meeting of the American Society of Anesthesiologists in Boston, Massachusetts.

It added that use of TrueVue Impedance in the US remained subject to FDA approval, with the submission made but not yet granted.

"The launch of the TrueVue system on the CardioQ-ODM+ platform is an exciting development for the company," said Deltex chief executive Ewan Phillips.

"It means we will now be marketing the world's first haemodynamic monitoring system which can be used across the whole patient pathway from awake, mobile outpatients of all ages through to sedated, critical care patients."

Phillips said the TrueVue system could be used by trainee staff, in non-critical situations, through to experienced specialists.

"It will also broaden the company's addressable market and positions us to supply hospitals with all their haemodynamic monitoring requirements on a single platform."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

DEMG Market Data

Currency UK Pounds
Share Price 1.30p
Change Today -0.100p
% Change -7.14 %
52 Week High 2.65
52 Week Low 0.90
Volume 1,035,182
Shares Issued 524.46m
Market Cap £6.82m
RiskGrade 445

DEMG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
44.04% below the market average44.04% below the market average44.04% below the market average44.04% below the market average44.04% below the market average
56.76% above the sector average56.76% above the sector average56.76% above the sector average56.76% above the sector average56.76% above the sector average
Price Trend Not Available
Income Not Available
Growth
56.84% below the market average56.84% below the market average56.84% below the market average56.84% below the market average56.84% below the market average
70.59% below the sector average70.59% below the sector average70.59% below the sector average70.59% below the sector average70.59% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

DEMG Dividends

No dividends found

Trades for 10-Jul-2020

Time Volume / Share Price
16:21 150,000 @ 1.21p
16:09 170,000 @ 1.33p
15:38 150,000 @ 1.21p
15:35 330,000 @ 1.35p
15:15 100,000 @ 1.20p

DEMG Key Personnel

Chair Nigel J Keen
CEO Andy Mears

Top of Page